N-Acetyltransferase 1 genetic polymorphism influences the risk of prostate cancer development

Cancer Letters

Volumn 136, Issue 1, 1999, Pages 83-87

  Fukutome, Kazuo ^a   Watanabe, Masatoshi ^a   Shiraishi, Taizo ^a   Murata, Mariko ^a   Uemura, Hiroji ^b   Kubota, Yoshinobu ^b   Kawamura, Juichi ^a   Ito, Haruo ^c   Yatani, Ryuichi ^a  

^a MIE UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b YOKOHAMA CITY UNIVERSITY   (Japan)

^c CHIBA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Genetic poslymorphism; N acetyltransferase 1; Prostate cancer; Risk analysis

Indexed keywords

ACYLTRANSFERASE; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER RISK; CONTROLLED STUDY; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE HYPERTROPHY; RISK ASSESSMENT;

ALLELES; ARYLAMINE N-ACETYLTRANSFERASE; CASE-CONTROL STUDIES; GENOTYPE; HETEROZYGOTE; HUMANS; ISOENZYMES; MALE; POLYMERASE CHAIN REACTION; POLYMORPHISM, GENETIC; PROSTATIC NEOPLASMS; RISK; RISK FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 0033044750     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0304-3835(98)00311-5     Document Type: Article

References (20)

1. Hill P., Wynder E.L., Garnes H., Walker A.R. Environmental factors, hormone status, and prostatic cancer. Prev. Med. 9:1980;657-666.
2. de Jong F.H., Oishi K., Hayes R.B., Bogdanowicz J.F., Raatgever J.W., van der Maas P.J., Yoshida O., Schroeder F.H. Peripheral hormone levels in controls and patients with prostatic cancer or benign prostatic hyperplasia: results from the Dutch-Japanese case-control study. Cancer Res. 51:1991;3445-3450.
3. Hayashi S., Watanabe J., Kawajiri K. High susceptibility to lung cancer analyzed in terms of combined genotypes of P450IA1 and Mu-class glutathione S-transferase genes. Jpn. J. Cancer Res. 83:1992;866-870.
4. Zhong S., Howie A.F., Ketterer B., Taylor J., Hayes J.D., Beckett G.J., Wathen C.G., Wolf C.R., Spurr N.K. Glutathione S-transferase mu locus: use of genotyping and phenotyping assays to assess association with lung cancer susceptibility. Carcinogenesis. 12:1991;1533-1537.
5. Hein D.W., Rustan T.D., Bucher K.D., Furman E.J., Martin W.J. Extrahepatic expression of the N-acetylation polymorphism toward arylamine carcinogens in tumor target organs of an inbred rat model. J. Pharmacol. Exp. Ther. 258:1991;232-236.
6. Kirlin W.G., Ogolla F., Andrews A.F., Trinidad A., Ferguson R.J., Yerokun T., Mpezo M., Hein D.W. Acetylator genotype-dependent expression of arylamine N-acetyltransferase in human colon cytosol from non-cancer and colorectal cancer patients. Cancer Res. 51:1991;549-555.
7. Sadrieh N., Davis C.D., Snyderwine E.G. N-acetyltransferase expression and metabolic activation of the food-derived heterocyclic amines in the human mammary gland. Cancer Res. 56:1996;2683-2687.
8. Bell D.A., Badawi A.F., Lang N.P., Ilett K.F., Kadlubar F.F., Hirvonen A. Polymorphism in the N-acetyltransferase 1 (NAT1) polyadenylation signal: association of NAT1*10 allele with higher N-acetylation activity in bladder and colon tissue. Cancer Res. 55:1995;5226-5229.
9. Jones R.F., Debiec-Rychter M., Schut H.J., Morse P., Haas G.P., Wang C.Y. N-acetyltransferase expression and heterocyclicamine adduct formation in human prostate. Proc. Am. Assoc. Cancer Res. 39:1998;635.
10. Shirai T., Sano M., Tamano S., Takahashi S., Hirose M., Futakuchi M., Hasegawa R., Imaida K., Matsumoto K., Wakabayashi K., Sugimura T., Ito N. The prostate: a target for carcinogenicity of 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP) derived from cooked foods. Cancer Res. 57:1997;195-198.
11. Vatsis K.P., Weber W.W. Structural heterogeneity of Caucasian N-acetyltransferase at the NAT1 gene locus. Arch. Biochem. Biophys. 301:1993;71-76.
12. Bell D.A., Stephens E.A., Castranio T., Umbach D.M., Watson M., Deakin M., Elder J., Hendrickse C., Duncan H., Strange R.C. Polyadenylation polymorphism in the acetyltransferase 1 gene (NAT1) increases risk of colorectal cancer. Cancer Res. 55:1995;3537-3542.
13. Japanese Urological Association, Japanese Pathological Society. General Rule for Clinical and Pathological Studies on Prostatic Cancer. 2nd edn. 1992;Kanehara Press, Tokyo.
14. Yu M.C., Skipper P.L., Taghizadeh K., Tannenbaum S.R., Chan K.K., Henderson B.E., Ross R.K. Acetylator phenotype, aminobiphenyl-hemoglobin adduct levels, and bladder cancer risk in white, black, and Asian men in Los Angeles, California. J. Natl. Cancer Inst. 86:1994;712-716.
15. Mashimo M., Suzuki T., Abe M., Deguchi T. Molecular genotyping of N-acetylation polymorphism to predict phenotype. Hum. Genet. 90:1992;139-143.
16. Parkin D.M., Muir C.S. Cancer Incidence in Five Continents. Comparability and quality of data. IARC Sci. Publ. 1992;45-173.
17. Yatani R., Chigusa I., Akazaki K., Stemmermann G.N., Welsh R.A., Correa P. Geographic pathology of latent prostatic carcinoma. Int. J. Cancer. 29:1982;611-616.
18. Jackson R.J., Standart N. Do the poly(A) tail and 3′ untranslated region control mRNA translation? Cell. 62:1990;15-24.
19. Badawi A.F., Hirvonen A., Bell D.A., Lang N.P., Kadlubar F.F. Role of aromatic amine acetyltransferases, NAT1 and NAT2, in carcinogen-DNA adduct formation in the human urinary bladder. Cancer Res. 55:1995;5230-5237.
20. Sturgeon S.R., Hartge P., Silverman D.T., Kantor A.F., Linehan W.M., Lynch C., Hoover R.N. Association between bladder cancer risk factors and tumor stage and grade at diagnosis. Epidemiology. 5:1994;218-225.